Outcome of cancer patients after atrial fibrillation ablation: Insights from the China‐AF registry

Abstract

BackgroundCancer has become significant comorbidity in patients with atrial fibrillation (AF). However, little is known about the efficacy and safety of AF ablation, the first‐line rhythm control strategy, in patients with cancer. This study aims to evaluate the incidence and risk of AF recurrence and safety endpoints in patients with cancer compared to the non‐cancer group after ablation.MethodsFrom August 2011 to December 2020, we consecutively enrolled cancer patients in the China‐AF cohort. We used propensity score matching (1:3) to select the control group and assessed the risk of AF recurrence and adverse events after ablation in cancer patients using a multivariable Fine and Gray competing risk model.ResultsA total of 203 patients with cancer were enrolled and 21 of them were active cancer, with a median follow‐up of 12.3 months. The cumulative incidence of AF recurrence was comparable between patients with and without cancer (43.8% vs. 51.1%; p = .88). No difference in the risk of AF recurrence, thromboembolism, major bleeding, and mortality was observed after adjusting confounders. Active cancer was not associated with an increased risk of AF recurrence compared to the stable disease (SHR = 1.32; 95% CI 0.72–2.43; p = .46). Cancer was associated with a low risk of cardiovascular hospitalization (SHR, 0.54; 95% CI, 0.36–0.81; p = .01). Subgroup analysis found that hematological malignancy was associated with a high risk of AF recurrence (SHR, 5.68; 95% CI, 3.00–10.8; p < .001).ConclusionsThis study suggests that catheter ablation could be feasible for rhythm control of AF patients with concomitant cancer.